Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL6065 Target Snapshot

Dihydrofolate reductase · SINGLE PROTEIN · Mycobacterium tuberculosis

Back to Search Search this target Browse approvals Evidence Card
73Compounds
22Assays
3Approved Drugs
56.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Dihydrofolate reductase shows approved-linked disease relevance led by tuberculosis. 4 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P9WNX1. Start with tuberculosis, then reuse UniProt P9WNX1 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with tuberculosis, then reuse UniProt P9WNX1 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 2 linked drugs
Open source guide
Disease program
tuberculosis

Dihydrofolate reductase shows approved-linked disease relevance led by tuberculosis. 4 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with tuberculosis because it currently carries approved-linked support. Linked drugs include AMINOSALICYLATE SODIUM, AMINOSALICYLIC ACID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Dihydrofolate reductase as ChEMBL target CHEMBL6065, mapped to UniProt P9WNX1. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Dihydrofolate reductase
SINGLE PROTEIN · Mycobacterium tuberculosis
As of 2026-09-14
ChEMBL target ID
CHEMBL6065
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P9WNX1
Dihydrofolate reductase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Dihydrofolate reductase is the right protein anchor across sources, using UniProt P9WNX1 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why tuberculosis is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameDihydrofolate reductase
Target TypeSINGLE PROTEIN
OrganismMycobacterium tuberculosis
UniProtP9WNX1
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelDihydrofolate reductase
UniProt AccessionP9WNX1
Component TypeProtein
Sequence Length161 aa

Dihydrofolate reductase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Dihydrofolate reductase, mapped to UniProt P9WNX1. Sequence length is 161 aa.

Mapped IDP9WNX1
Review nameDihydrofolate reductase
OrganismMycobacterium tuberculosis
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Dihydrofolate reductase shows approved-linked disease relevance led by tuberculosis. 4 more disease programs remain visible in the same review block.

Approved-linked Approved
tuberculosis
2 linked drugs · 2 direct · 2 efficacy
Linked drugAMINOSALICYLATE SODIUM
Linked drugAMINOSALICYLIC ACID
Late clinical Phase III
pulmonary tuberculosis
1 linked drug · 1 direct · 1 efficacy
Linked drugAMINOSALICYLIC ACID
Clinical signal Phase II
Crohn's disease
1 linked drug · 1 direct · 1 efficacy
Linked drugAMINOSALICYLIC ACID
Clinical signal Phase II
ulcerative colitis
1 linked drug · 1 direct · 1 efficacy
Linked drugAMINOSALICYLIC ACID
Mechanism-linked
osteomyelitis
1 linked drug · 1 direct · 1 efficacy
Linked drugAMINOSALICYLIC ACID
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with tuberculosis because it currently carries approved-linked support. Linked drugs include AMINOSALICYLATE SODIUM, AMINOSALICYLIC ACID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasetuberculosis
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

3
Approved
1
Phase III
Assay Mix

Activity Type Distribution

IC5053.0
KI1.0
KD2.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5279457 9.02 IC50 0.96 Preclinical
CHEMBL64 9.0 Ki 1.0 Approved
CHEMBL1904209 8.22 IC50 6.0 Preclinical
CHEMBL526013 8.09 IC50 8.2 Preclinical
CHEMBL34259 8.08 IC50 8.25 Approved
CHEMBL526243 8.0 IC50 10.1 Preclinical
CHEMBL5629885 7.77 Kd 17.0 Preclinical
CHEMBL586115 7.65 IC50 22.4 Preclinical
CHEMBL3245817 7.52 IC50 30.0 Preclinical
CHEMBL3245816 7.3 IC50 50.0 Preclinical
Distribution

pChEMBL Value Distribution

6
5.0
1
5.5
3
6.0
1
6.5
3
7.0
3
7.5
5
8.0
0
8.5
2
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

METHOTREXATE
CHEMBL34259
Approved 1953
Properties Compare Identifier
ISONIAZID
CHEMBL64
Approved 1952
Properties Compare Identifier
Assay Landscape

Assay Landscape

22
Total Assays
46
Tested Compounds
1
Assay Types
Binding — 22 assays, 46 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 15 21 6.2
assay format 4 9 6.7
cell-based format 3 16 4.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine